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of IMRT, SBRT, and 3D treatments was 50%, 28%, and 
22%,respectively. More than 150 real time adaptive fractions 
were delivered to more than 45 patients. We have also 
demonstrated that the system is capable of determining true 
delivered doses based on daily MR images.  
 
Conclusions: Based on the first two years of clinical 
operation, routine MR-IGRT program is practical, with ability 
of treating a broad spectrum of cancer sites, significant 
number of patients in a day, and systematic delivery of 
advanced and adaptive treatments. 
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The MR-linac combines a 1.5 Tesla MRI and a modern 7MV 
Linac into a single device that can simultaneously produce 
diagnostic quality MRI images and deliver highly conformal 
IMRT based treatments. The introduction of in room MR-linac 
based imaging allows for superior soft tissue contrast of 
tumor and surrounding normal tissues. This functionality 
enables enhanced re-positioning and adaptive radiation 
therapy to account for inter-treatment positioning errors, 
organ deformation, organ movement, and tumor response. 
Additionally, this combined device provides functionality to 
account for intra-treatment motion and has the potential to 
acquire multi-parametric functional sequences at the time of 
treatment. 
The addition of the MR-linac to a radiation therapy clinic 
poses novel challenges related to the the presence of the 
magnetic field and the configuration of the device. Prevailing 
regulations concerning room access, shielding, and adjacency 
to other treatment units and medical equipment must be 
considered when siting the device. Personnel must possess or 
acquire the skill sets and competencies to safely operate an 
MRI and Linac treatment machine. This training should be in 
place prior to installation of the device. Experience with MRI 
based simulation and treatment planning is also a 
prerequisite for MR-linac based treatment delivery. MRI 
based simulation requires attention to the size and material 
of patient positioning devices, MRI coil and table top design. 
Optimal MRI sequences to facilitate region specific tumor and 
normal tissue delineation that may differ from institutional 
diagnostic sequences must be developed. Image distortion is 
routinely managed as part of modern MRI imaging but the use 
of MRI for simulation and the MR-linac for guidance and 
treatment requires a QA process that is nuanced to these 
specific workflows.  
It is anticipated that the work flow for the MRI-linac device 
will be divided into two general scenarios. The first utilizes 
pre-treatment MRI images for patient repositioning to correct 
translational and or rotational errors. This is similar to the 
current cone beam CT image guidance workflow with the 
addition of superior soft tissue contrast. Additionally, the 
intra-fraction imaging will provide superior ability to manage 
tumor motion. The second approach adds plan adaption to 
the MRI based treatment guidance workflow to account for 
deformation, volume, and independent motion changes of 
the targets and organs at risk. The frequency of online or 
offline adaption will depend on the characteristics of tumor 
response and anatomical location.  
An international research consortium has been formed to 
allow for an evidence-based introduction of the MR-linac 
technology and to address how the technology could be used 
to achieve an optimized radiation treatment approach in 
terms of tumor control and toxicity. The MR-linac consortium 
structure is outlined in Figure 1. Nine tumor site groups have 
been selected to start consortium based clinical studies 
based on the expected clinical benefit (either increased local 
control, survival, decreased toxicity or improved quality of 
life). The first nine consortium-broad tumor sites include: 
rectum, esophagus, oropharynx, pancreas, prostate, breast, 
cervix, brain and lung. Each consortium institute coordinates 
one or more Tumor Site Groups (TSG). To achieve the clinical 
introduction of the MR-linac in a safe and step wise manner, 
an adapted version of the IDEAL framework, the R-IDEAL 
(Radiotherapy, Idea, Development, Exploration, Long-term 
study) framework, will be used to conduct the proposed 




Figure 1. Organizational structure clinical working groups MR-
linac Consortium (CSC-clinical steering committee, MAB-
methodology advisory board, DMTF-data management task 
force, TSG-tumor site group) 
References: McCulloch P, Altman DG, Campbell WB, et. al. 
No surgical innovation without evaluation: the IDEAL 
recommendations. Lancet 2009:374:1105-12 
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Soon after the introduction of MRI in radiology it became part 
of treatment planning in radiotherapy and in brachytherapy. 
Especially in gynecological brachytherapy MRI was used 
during the process of target definition. But also in other 
clinical sites MRI before brachytherapy became an essential 
tool for correct staging, treatment decision making and 
target volume definition. The important point was the use of 
MRI with the brachytherapy applicators in-situ. By this 
process the image series contain both, the delivery device 
and the anatomy including tumour, target and organs at risk. 
This enables a real adaptive planning strategy, as the 
treatment planning is based directly on these image series. 
Imaging of a fixed geometry of delivery device inside the 
anatomy is not different to in-room imaging used for external 
beam with a linac or other device as delivery device outside 
the patient. The aim of in room imaging is to depict the 
situation during dose delivery as close as possible. The 
question is how much change of the target and organs at risk 
happens between imaging and dose delivery. In external 
beam this is performed almost simultaneously without 
essential changes, while in brachytherapy the movement of 
patients from an imaging room to a treatment room might 
impose changes. This question was analyzed and debated for 
years, often using inappropriate methodologies as 
registration to bony landmarks. Only recently multicenter 
studies showed that for cervix cancer brachytherapy for 
example the relation of applicators to target is stable with 
minor variations. However, more variation may occur for 
adjacent OARs. Various methods are investigated on how to 
minimize such uncertainties. One is to perform MRI in-room 
